BioSpace News Archive

Mitsubishi Tanabe Pharma America, Inc. announced two presentations on investigational ND0612 in Parkinson’s disease will be shared at the International Association of Parkinsonism and Related Disorders XXVIII World Congress on Parkinson’s Disease and Related Disorders, being held in Chicago, Ill., May 13-16.

Novavax, Inc. announced that the Singapore Health Sciences Authority has granted extended interim authorization and the Ministry of Health has included Nuvaxovid™ into the National Vaccination Programme as a non-mRNA option for adolescents aged 12 through 17 for active immunization to prevent COVID.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its first quarter 2023 financial results and provided a business update.

PinCell announced that two pre-clinical studies carried out in Japan by a specialized team indicate that its lead candidate, PC111, can be effective in treating Stevens-Johnson Syndrome, an acute skin disease with no approved therapy.

Novarad’s VisAR, a surgical navigation system that uses augmented reality, has received clearance from Indonesia’s FDA for intraoperative use in stereotactic spinal surgery.

Amarin Corporation plc (NASDAQ:AMRN) today highlighted new data describing the benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) on coronary physiology, which was published in the European Heart Journal - Cardiovascular Imaging, and plaque progression, which was presented at the American Heart Association’s Vascular Discovery 2023 meeting in Boston, MA, May 10-13.

Xenetic Biosciences, Inc., a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, announced it will effect a one-for-ten reverse stock split of its authorized, issued and outstanding common stock.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Clene Inc. and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, announced its first quarter 2023 financial results and provided recent operating highlights for the clinical programs in amyotrophic lateral sclerosis and multiple sclerosis.

Innate Pharma SA announced the voting results of its shareholders at the Annual General Meeting, which took place on May 12, 2023, in Marseille.